bluebird bio, Inc. (NASDAQ:BLUE) Given Consensus Rating of “Hold” by Analysts

bluebird bio, Inc. (NASDAQ:BLUE) has been given a consensus recommendation of “Hold” by the nine analysts that are covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, five have given a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $49.14.

Several analysts have commented on the stock. StockNews.com assumed coverage on shares of bluebird bio in a research note on Friday, December 20th. They issued a “sell” rating on the stock. Royal Bank of Canada reiterated a “sector perform” rating and issued a $80.00 price target on shares of bluebird bio in a research note on Friday, November 15th. Bank of America cut shares of bluebird bio from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $60.00 to $10.00 in a research note on Friday, November 15th. JPMorgan Chase & Co. cut shares of bluebird bio from a “neutral” rating to an “underweight” rating in a research report on Friday, November 15th. Finally, Barclays upped their target price on shares of bluebird bio from $2.00 to $40.00 and gave the company an “overweight” rating in a research report on Tuesday, December 31st.

bluebird bio Stock Up 5.6 %

Shares of BLUE stock opened at $6.39 on Thursday. The stock has a market cap of $62.11 million, a P/E ratio of -0.17 and a beta of 0.68. bluebird bio has a 52 week low of $5.80 and a 52 week high of $38.40. The company has a quick ratio of 0.33, a current ratio of 0.51 and a debt-to-equity ratio of 0.37. The company’s fifty day simple moving average is $8.17 and its two-hundred day simple moving average is $10.31.

Hedge Funds Weigh In On bluebird bio

Several hedge funds have recently added to or reduced their stakes in BLUE. AQR Capital Management LLC grew its holdings in bluebird bio by 315.3% during the 2nd quarter. AQR Capital Management LLC now owns 1,334,519 shares of the biotechnology company’s stock valued at $1,223,000 after purchasing an additional 1,013,144 shares during the last quarter. BNP Paribas Financial Markets grew its holdings in bluebird bio by 2,270.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 371,224 shares of the biotechnology company’s stock valued at $193,000 after purchasing an additional 355,562 shares during the last quarter. FMR LLC grew its holdings in bluebird bio by 8.1% during the 3rd quarter. FMR LLC now owns 2,481,965 shares of the biotechnology company’s stock valued at $1,289,000 after purchasing an additional 186,903 shares during the last quarter. Barclays PLC grew its holdings in bluebird bio by 273.7% during the 3rd quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock valued at $130,000 after purchasing an additional 184,605 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in bluebird bio by 3.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,683,042 shares of the biotechnology company’s stock valued at $2,433,000 after purchasing an additional 166,771 shares during the last quarter. 87.43% of the stock is currently owned by institutional investors.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.